PANGYO, KOREA - Merck Korea (Managing Director: Dr. Michael Grund), the Korean affiliate of a global pharmaceutical and chemical company Merck, will hold the ‘Merck Millipore Vaccine Technology Seminar 2014’ at Bio-manufacturing Sciences & Training Center (BSTC) of Korea Bio Park in Pangyo, Gyeonggi-do at 1 p.m. today.
At the event, Dr. Nina Kreiskoether (Portfolio Development Manager for Cell Culture Media), Dr. Priyabrata Pattnaik (Director – Worldwide Vaccine Initiative), Mr. Michael Payne (Senior Technical Bio-safety Consultant at Merck Millipore) and Dr. George Adams(Vaccine Program Asia-Pacific/India Market Manager) will introduce information and offer professional technology through Q&A session.
The seminar is prepared to introduce new vaccine trend, regulatory, the latest technology trends, application for efficiency of product development and production process with 50 vaccine experts of Korean and foreign pharmaceutical companies. Sharing opinions with customers will make an opportunity to bring leading technology.
BSTC offers process development and training program to bio companies to feel close to Merck’s products. BSTC supports customers’ process development/production with high-quality and enter biopharmaceutical market through demonstration of Merck Millipore product for customers’ material. Additionally, BSTC supports consulting, presentation, seminar inviting customers and make an opportunity to meet Merck Millipore products.
<Q&A with Dr. Priyabrata Pattnaik>
Q1. What is the meaning of this seminar and business plan of Merck in Korea?
A1. Vaccines are the most cost effective healthcare intervention that has positive impact on life of millions of people. With emergence new disease, pandemics, and national security concerns vaccines are of critical importance to economic sustainability. Korea has stepped up national effort to become self reliant concerning vaccine development production, at least for the essential vaccines covered under national immunization program. This is a very exciting time for field of vaccine where several manufacturers in Korea has geared up efforts and has rich pipeline of molecule in development. Merck Millipore provides tools, technologies and services to the pharmaceutical and biotech industries. As an integral part of this community, we understand the complexity and risk faced by our customers, and work in close partnership with them to ensure their success.
Q2. Why is Asia region important in vaccine field and what is the objective of Merck?
A2. In last several years, we have had a strong focus on the vaccine industry, including that in Asia which is the one of the fastest growing regions for vaccine development and manufacturing. Our objective is to deliver innovative and integrated products and services that address the evolving needs of vaccine developers and manufacturers. Vaccine Technology Seminar at Seoul on 13th of March is one such effort to support vaccine manufacturers aimed at sharing knowledge, know-how and recent advances on the area of vaccine development and manufacturing.”
[Agenda of the Seminar]
1. Trends and technologies for upstream processing in vaccine production
- Speaker: Dr. Nina Kreikoether
2. Nucleic acid removal from vaccine processes – choices and challenges
- Speaker: Charles Park
3. Expediting vaccine development and manufacturing
- Speaker: Dr. Priyabrata Pattnaik
4. Consideration of single use implementation in vaccine manufacturing
- Speaker: Michael Payne
5. Vaccine formulation: What is in it for Asia
- Speaker: George Adams